Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT: Belatacept as First-line Immunosuppression in Kidney Transplantation
2004-003635-31Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2005
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of belatacept in kidney transplant (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Composite of subject and graft outcomes and Measured glomerular filtration rate at 12 months. Started Nov 2005; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2004-003635-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003635-31.